SecBot SecBot
Biotech Drug Report Generated Aug 17, 2026

SNDX-62122

SNDX·Syndax Pharmaceuticals Inc
NEUTRAL
Drug Impact Rating2/10
Trial phase
Preclinical
Time to market
Unknown, many years out. IND is targeted for 2027 and Phase 1 follows, so any approval (if the drug ever gets there) is realistically years beyond that.
Why 2/10
No hard, dated binary exists for SNDX-62122 itself in the next ~12 months: it is a preclinical asset with an IND submission only targeted for 2027 (no PDUFA, no pivotal readout), so per the rubric it scores 2, the closest catalyst is the separate revumenib Phase 1/2 proof-of-principle trial in myelofibrosis expected to initiate in Q4 2026.
Actionable Insight NEUTRAL

Treat SNDX-62122 as a long-dated, option-like pipeline line item, not a near-term trade catalyst, there is no dated binary for this molecule itself within ~12 months (IND is a 2027 target). Investors positioned in SNDX should instead focus on the Q4 2026 axatilimab IPF/cGVHD data and the Q4 2026 start of the revumenib myelofibrosis trial, which is the earliest real-world read on the menin-in-MF hypothesis this drug depends on.

Price Chart

Loading chart...

Executive Summary

SNDX-62122 is Syndax Pharmaceuticals' (Nasdaq: SNDX) first wholly owned next-generation menin inhibitor, unveiled at the company's July 14, 2026 R&D event for development in myelofibrosis. It is preclinical: no clinical trial has started, and the company targets an IND submission in 2027, with development to be informed and de-risked by a Phase 1/2 proof-of-principle trial of its already-approved menin inhibitor revumenib (Revuforj) in myelofibrosis that is expected to start in Q4 2026 with initial data in 2H 2027. For a non-medical investor, this is an early, option-like pipeline asset at a commercial-stage company, the stock's near-term drivers are the late-stage programs (axatilimab IPF/cGVHD readouts, expected 4Q26) and commercial ramp of Revuforj/Niktimvo, not SNDX-62122.

How It Works

A menin inhibitor blocks a protein (menin) that acts as a co-factor "switch" helping certain genes drive blood cancers. Syndax's already-approved drug revumenib (Revuforj) is also a menin inhibitor, approved in a form of acute myeloid leukemia. SNDX-62122 is described as a next-generation menin inhibitor, the first candidate from Syndax's own library of these compounds, chosen to move menin inhibition into myelofibrosis, a bone-marrow cancer where the company says there is high unmet need, though the mechanism's benefit in that disease is still unproven.

Trial Status

No human trials yet. Unveiled July 14, 2026; IND submission targeted for 2027 with Phase 1 initiation to follow. The company plans to de-risk the program with a Phase 1/2 proof-of-principle trial of revumenib in myelofibrosis (expected to initiate Q4 2026, initial data 2H 2027) before/alongside advancing SNDX-62122. Independent trackers (AdisInsight, Synapse) list the drug as preclinical.

The Two-Sided Case

▲ Bull Case4
Wholly owned and internally developed: SNDX-62122 is the first candidate from Syndax's next-generation menin inhibitor library, giving the company a follow-on asset it fully controls (finance.yahoo.com; ir.syndax.com).
Program is designed to be de-risked: development will be informed by the revumenib Phase 1/2 proof-of-principle trial in myelofibrosis, expected to initiate Q4 2026 with initial data 2H 2027, so Syndax gets an early clinical read on the menin-in-myelofibrosis thesis before SNDX-62122's own IND (ir.syndax.com; syndax.com/pipeline).
Parent company is commercial-stage with two FDA-approved drugs (Revuforj, Niktimvo) annualizing at roughly $200M combined as of 1Q26, and analysts are bullish: 18 of 19 ratings are Buy/Strong Buy with a mean price target of ~$37.9 vs. a ~$19.84 stock price.
Myelofibrosis is a disease area with high unmet need, giving the asset a potentially large market if menin inhibition works there (minichart.com.sg; bioworld.com).
▼ Bear Case5
Pure preclinical risk: no clinical data exist, the IND is not targeted until 2027, and typical early-stage oncology attrition means most candidates never reach approval (adisinsight.springer.com; synapse.patsnap.com).
The myelofibrosis mechanism is unproven, even revumenib, the company's own menin inhibitor, is only approved in NPM1-mutated AML, so SNDX-62122 depends on a thesis that has yet to show clinical validation.
SNDX-62122 is a small part of the SNDX story: near-term stock drivers are axatilimab IPF/cGVHD data (expected 4Q26) and commercial execution, not this preclinical asset, so standalone news around it is unlikely to move the stock much.
Offsetting signals: CEO and CMO insider sales (10b5-1) in mid-2026, several large tracked funds trimmed/exited in 2025-Q4/2026-Q1, and FINRA short-volume flow was elevated (weighted short-volume ratio ~0.58 on 2026-08-14), context of mixed positioning.
Historically, SNDX shares have traded DOWN around past FDA approval catalysts (avg ~-6.8% 1-day on the two recorded approvals), a reminder that regulatory news doesn't automatically reward this stock.

Upcoming Catalysts

  • Revumenib Phase 1/2 proof-of-principle trial in myelofibrosis initiation (expected Q4 2026), the closest read-through for the menin-in-MF thesis behind SNDX-62122
  • Initial revumenib myelofibrosis data (expected 2H 2027)
  • SNDX-62122 IND submission (targeted 2027) and Phase 1 initiation
  • SNDX-4321 IND submission (targeted year-end 2026), the other pipeline asset unveiled at the same R&D event
  • Company-level, not drug-specific: axatilimab IPF (MAXPIRe) Phase 2 and cGVHD data readouts expected 4Q26

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Syndax Pharmaceuticals Inc 8-K SNDX ·Originating report

Sources · 11

Hover a chip for the title
1 ir.syndax.com2 synapse.patsnap.com3 adisinsight.springer.com4 bioworld.com5 pienomial.com6 quartr.com7 minichart.com.sg8 stocktitan.net9 syndax.com10 globenewswire.com11 sec.gov